M&A Deal Summary

C. R. Bard Acquires Rochester Medical

On September 4, 2013, C. R. Bard acquired medical products company Rochester Medical for 262M USD

Acquisition Highlights
  • This is C. R. Bard’s 17th transaction in the Medical Products sector.
  • This is C. R. Bard’s largest (disclosed) transaction.
  • This is C. R. Bard’s 20th transaction in the United States.
  • This is C. R. Bard’s 3rd transaction in Minnesota.

M&A Deal Summary
Date 2013-09-04
Target Rochester Medical
Sector Medical Products
Buyer(s) C. R. Bard
Deal Type Add-on Acquisition
Deal Value 262M USD
Advisor(s) Piper Jaffray Companies (Financial)
Dorsey & Whitney LLP (Legal)

Target

Rochester Medical

Stewartville, Minnesota, United States
website
Rochester Medical Corp. is a developer and supplier of silicone urinary incontinence and urine drainage products. We develope silicone self-adhering male external catheters as well as the first antimicrobial intermittent catheters. Our anti-infection Foley catheter remains the only non-latex Foley proven to reduce catheter-associated urinary tract infections.

Search 193,103 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

C. R. Bard

Murray Hill, New Jersey, United States

website

Category Company
Founded 1907
Sector Medical Products
Employees14,900
Revenue 3.7B USD (2016)
DESCRIPTION
Entrance to C. R. Bard's corporate headquarters in Murray Hill, New Jersey.
Entrance to C. R. Bard's corporate headquarters in Murray Hill, New Jersey.

C. R. Bard, Inc. is a multinational developer, manufacturer, and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology, and surgical specialties. C. R. Bard was formed in 1907 and is based in Murray Hill, New Jersey.

DEAL STATS #
Overall 21 of 23
Sector (Medical Products) 17 of 18
Type (Add-on Acquisition) 20 of 22
State (Minnesota) 3 of 3
Country (United States) 20 of 22
Year (2013) 2 of 3
Size (of disclosed) 1 of 14
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-08-19 Medafor

Minneapolis, Minnesota, United States

Medafor, Inc., is a developer and supplier of plant based hemostatic agents. Medafor develop and market its unique, patented hemostatic technology based on engineered biopolymeric microporous particles.

Buy $200M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-10-23 NeoMend

Irvine, California, United States

NeoMend, Inc., is a developer and supplier of sprayable surgical sealants and anti-adhesion products. An innovator in sealant and adhesion-prevention products for the surgical marketplace focused on the design, development and commercialization of innovative surgical sealants and adhesion prevention products derived from the Progel® technology platform.

Buy $140M
Mergr

Product

Company

Legal